MORE►
Colossal Biosciences
Dr. Beth Shapiro and Colossal Co-Founder and CEO Ben Lamm with a stuffed dodo. [Photo: Colossal]
Texas-Based Colossal Achieves Unicorn Status With $150M Series B Raise, Plans To ‘De-Extinct’ the Dodo Bird
by David Seeley | Jan 31, 2023
Colossal says its efforts could help boost "the U.S. high-tech advantage." Its gene editing technologies "will make waves across sectors—in agriculture with new biofuels and preserving biodiversity, as well as in human health through improved gene therapy and vaccine development," the company said.
by Kevin Cummings |
Oct 24, 2022
The Biotech+ Hub at Pegasus Park in Dallas has been attracting more and more life science startups and university teams. Now a whole herd of Mustangs are about to stampede there. The SMU Institute for Computational Biosciences at Pegasus Park will have space at the 23-acre development. SMU researchers from a variety of disciplines will be focusing on bio-scientific discoveries, leveraging advanced computational algorithms and technologies.
"We're excited to give SMU faculty this new opportunity to pursue world-changing research for good and to do so in close proximity to a broad range of academic, medical, corporate, and non-profit collaborators," says SMU Provost Elizabeth Loboa. "We're excited to give SMU faculty this new opportunity to pursue world-changing research for good and to do so in close proximity to a broad range of academic, medical, corporate, and non-profit collaborators," says SMU Provost Elizabeth Loboa.
"We're excited to give SMU faculty this new opportunity to pursue world-changing research for good and to do so in close proximity to a broad range of academic, medical, corporate, and non-profit collaborators," says SMU Provost Elizabeth Loboa. "We're excited to give SMU faculty this new opportunity to pursue world-changing research for good and to do so in close proximity to a broad range of academic, medical, corporate, and non-profit collaborators," says SMU Provost Elizabeth Loboa.
MORE►
by Kevin Cummings |
Oct 17, 2022
In this week’s North Texas deal flow, you’ll also find news about Mavenir’s $155M raise, Pinnacle Realty Advisors raising $5M for ‘brokerage-as-a-service’ platform, Exela Technologies taking its European business unit public, American Airlines’ hydrogen fuel distribution investment, and more.
MORE►
by David Seeley |
Oct 11, 2022
The Central Intelligence Agency has invested in Colossal through its nonprofit VC investment arm, In-Q-Tel, reports The Intercept. Named in honor of Q—the tech genius from the James Bond novels and movies—the VC firm was founded in 1999 to keep U.S. intelligence agencies on the cutting edge of "innovative and impactful technologies coming out of Silicon Valley and beyond."
So why Colossal? "Strategically, it’s less about the mammoths and more about the capability," In-Q-Tel says.
MORE►
The Tasmanian tiger went extinct due to human hunting nearly 100 years ago. Now Dallas-based Colossal Biosciences aims to bring it back with the help of "marsupial biobanking." [Image: Colossal Biosciences]
Dallas-Based Colossal Is ‘De-Extincting’ the Tasmanian Tiger
by David Seeley | Aug 16, 2022
Colossal is already working to "de-extinct" the woolly mammoth via a mammoth-elephant hybrid project. Now the Tasmanian tiger—which went extinct nearly 100 years ago due to human hunting—is the second species Colossal is seeking to bring back.
"We’re thrilled to be collaborating with Andrew Pask and the University of Melbourne to restore this amazing animal to Earth," said Ben Lamm, Colossal's co-founder and CEO.
MORE►
by Quincy Preston and David Seeley |
Mar 22, 2022
Dallas' status as a growing biotech center got a lift with the official opening of BioLabs, a new coworking space at the Biotech+ Hub at Pegasus Park. The 37,000-square-foot facility offers shared wet labs and office space for up to 35 life science startups.
BioLabs' goal: to serve as the epicenter for life science innovation in North Texas, and to empower biotech trailblazers pursing their next breakthrough.
BioLabs' goal: to serve as the epicenter for life science innovation in North Texas, and to empower biotech trailblazers pursing their next breakthrough.
MORE►
by Quincy Preston and David Seeley |
Mar 9, 2022
Colossal launched last September with a plan to "de-extinct" the woolly mammoth by using CRISPR genetic engineering to create a mammoth-elephant hybrid.
With a total raise of $75 million to date, the startup aims to
have its first set of mammoth-elephant hybrid calves "in 4 to 6 years," co-founder and CEO Ben Lamm told us. But Colossal's goals extend much further—with the potential "to advance human health, enhance food production, reduce environmental impact, and optimize animal health and welfare."
MORE►
by David Seeley |
Sep 13, 2021
It's not "Jurassic Park," but it's almost as amazing. Hypergiant founder Ben Lamm is launching a new biosciences and genetics startup—Colossal—with $15 million in private funding. The goal: Use genomics to "de-extinct" the woolly mammoth and re-wild it on the Arctic tundra. Lamm's co-founder, Harvard geneticist Dr. George Church, says this "grand vision" could lead to big opportunities in conservation, biodiversity, carbon sequestration, and more.
MORE►
